<DOC>
	<DOCNO>NCT01484080</DOCNO>
	<brief_summary>The investigator plan study efficacy combination weekly paclitaxel + BIBF 1120 early breast cancer use neoadjuvant schedule randomize phase-II trial design , compare efficacy vs. weekly paclitaxel alone , follow surgery subsequent standard care ( anthracycline base chemotherapy , radiation hormonal blockade ) .</brief_summary>
	<brief_title>Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed BIBF 1120 Plus Paclitaxel Early HER-2 Negative Breast Cancer With Proteomic Dynamic Imaging Correlates</brief_title>
	<detailed_description>This open-label , multicenter , Phase I dose-escalation study assess safety tolerability oral ( PO ) BIBF 1120 administer intravenous ( IV ) paclitaxel ( 80 mg/m2 day 1 , 8 15 every 3 week ) patient breast cancer ( see Figure 1 study flow chart ) . BIBF 1120 administered twice daily PO 21 consecutive day ( Days 1 21 ) 3-week cycle ( morning dose skip paclitaxel administration day )</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Signed Informed Consent Form 2 . Patients ≥18 yearold 3 . Histological diagnosis localize breast cancer primary tumour 2 cm long diameter ( measure mammography MRI ) . Any nodal status allow operable tumour diagnosis . Multicentricity allow . 4 . HER 2 negative ( Inmunohistochemistry + +++ ; FISH CISH ( ) ; equivalent HER2/CEP17 copy 2 : HER2 result ++/+++ need FISH/CISH confirmation . 5 . Measurable disease primary lesion &gt; 2 cm . RECIST v1.1 criterion 6 . ECOG 01 7 . Adequate hematologic , renal hepatic function , define follow laboratory result obtain within 14 day prior randomization/registration : Absolute granulocyte count &gt; 1.5 x 109/L Absolute platelet count &gt; 100 x 109/L Hemogobin &gt; 10 g/dL Serum creatinine &gt; 1.5 x UNL calculate creatinine clearance &gt; 50 ml/min Serum bilirubin &lt; 1.25 UNL AST/ALT &lt; 1.5 time UL 8 . Premenopausal woman must effective birth control ( nonhormone ) continue use duration study even 6 month later . 9 . For female childbearing potential , negative pregnancy test within prior 7 day study enrolment 10 . Life expectancy &gt; 6 month 1 . Metastatic nonsurgical breast cancer ( include inflammatory ) . 2 . Locally breast cancer primary lesion 2 cm . In case multicentricity , admit study unless lesion would length . 3 . Previous concurrent treatment kind breast cancer : hormonal agent , conventional cytotoxic drug , radiation therapy , target drug , bisphosphonates , monoclonal antibody surgery . Chemoprevention tamoxifen raloxifene allow far treatment interrupted upon diagnosis least 4 week prior inclusion . Same criterion postmenopausal hormonal replacement therapy . Hormonal contraceptive discontinue . 4 . HER2 positive breast cancer define overexpression Immunochemistry HER2 3+ 2+ positive FISH/CISH 5 . Male patient . 6 . Pregnancy , lactation breastfeeding . 7 . Active malignancy side ( include contralateral synchronous breast cancer ) besides nonmelanoma skin cancer ductal/lobular breast cervix situ carcinoma , colon situ carcinoma accurately treat well tumour diagnosis &gt; 5 year prior registration without sign progression present time . 8 . Concurrent serious medical condition myocardial infarction within 6 month prior entry , congestive heart failure , unstable angina , active cardiomyopathy , unstable ventricular arrhythmia , uncontrolled hypertension ( NYHA criterion ) , uncontrolled psychotic disorder , serious active infection , active peptic ulcer disease , psychiatric illness , HIV infection , active hepatitis , COPD medical condition might aggravate treatment limit compliance . 9 . Inability take oral medication 10 . History malabsorption syndrome 11 . Proven allergy paclitaxel BIBF 1120 . 12 . Grade ≥2 peripheral neuropathy . 13 . Major surgery within 4 week registration ( breast cancer surgery regardless time exclusion criterion ) . 14 . Inability comply study followup procedure . 15 . Anticoagulation therapy ( except lowdose heparin / wash heparin need maintain permanent intravenous device ) antiplatelet therapy ( except treatment low dos aspirin &lt; 325 mg per day . 16 . History hemorrhagic thromboembolic event clinically significant last 6 month . 17 . Known hereditary predisposition bleed thrombosis</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>